A novel high‐risk model identified by epithelial–mesenchymal transition predicts prognosis and radioresistance in rectal cancer
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23797 ↗At a glance
Journal article in Molecular Carcinogenesis, 2024. Written by Feiyu Qin and 8 co-authors. Institution: Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, China. Major MEDLINE topics: Epithelial-Mesenchymal Transition, Rectal Neoplasms, Radiation Tolerance, Gene Expression Regulation, Neoplastic. Cited 4 times so far (Crossref); 67 references. Funded by: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Top Talent Support Program.
Abstract (original language)
Many studies have shown that tumor cells that survive radiotherapy are more likely to metastasize, but the underlying mechanism remains unclear. Here we aimed to identify epithelial–mesenchymal transition (EMT)‐related key genes, which associated with prognosis and radiosensitivity in rectal cancer. First, we obtained differentially expressed genes by analyzing the RNA expression profiles of rectal cancer retrieved from The Cancer Genome Atlas database, EMT‐related genes, and radiotherapy‐related databases, respectively. Then, Lasso and Cox regression analyses were used to establish an EMT‐related prognosis model (EMTPM) based on the identified independent protective factor Fibulin5 (FBLN5) and independent risk gene EHMT2 . The high‐EMTPM group exhibited significantly poorer prognosis. Then, we evaluated the signature in an external clinical validation cohort. Through in vivo experiments, we further demonstrated that EMTPM effectively distinguishes radioresistant from radiosensitive patients with rectal cancer. Moreover, individuals in the high‐EMTPM group showed increased expression of immune checkpoints compared to their counterparts. Finally, pan‐cancer analysis of the EMTPM model also indicated its potential for predicting the prognosis of lung squamous cell carcinoma and breast cancer patients undergoing radiotherapy. In summary, we established a novel predictive model for rectal cancer prognosis and radioresistance based on FBLN5 and EHMT2 expressions, and suggested that immune microenvironment may be involved in the process of radioresistance. This predictive model could be used to select management strategies for rectal cancer.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, China.
- Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
- Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, China.
ORCID profiles: Yuan Yin
Funding
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Top Talent Support Program
- Six Talent Peaks Projects of Jiangsu Province
- High Level Health Talent Project of Jiangsu Province
Cite
APA
Qin, F., Bian, Z., Jiang, L., Cao, Y., Tang, J., Ming, L., Qin, Y., Huang, Z., & Yin, Y. (2024). A novel high‐risk model identified by epithelial–mesenchymal transition predicts prognosis and radioresistance in rectal cancer. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23797
Vancouver
Qin F, Bian Z, Jiang L, Cao Y, Tang J, Ming L, et al. A novel high‐risk model identified by epithelial–mesenchymal transition predicts prognosis and radioresistance in rectal cancer. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23797
BibTeX
@article{Qin2024,
author = {Qin, Feiyu and Bian, Zehua and Jiang, Lingzhen and Cao, Yulin and Tang, Junhui and Ming, Liang and Qin, Yan and Huang, Zhaohui and Yin, Yuan},
title = {A novel high‐risk model identified by epithelial–mesenchymal transition predicts prognosis and radioresistance in rectal cancer},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23797}
}
EUVIMED